Affiliation:
1. Calico Life Sciences LLC South San Francisco California USA
2. AbbVie North Chicago Illinois USA
3. AbbVie Deutschland GmbH & Co. KG Ludwigshafen Germany
4. Texas Christian University Fort Worth Texas USA
Abstract
AbstractAimCharacterize Growth Differentiation Factor 15 (GDF15) as a secreted biomarker of the integrated stress response (ISR) within the central nervous system (CNS).MethodsWe determined GDF15 levels utilizing in vitro and in vivo neuronal systems wherein the ISR was activated. Primarily, we used the murine model of vanishing white matter disease (VWMD), a neurological disease driven by persistent ISR in the CNS, to establish a link between levels of GDF15 in the cerebrospinal fluid (CSF) and ISR gene expression signature in the CNS. GDF15 was also determined in the CSF of VWM patients.ResultsGDF15 expression was increased concomitant to ISR activation in stress‐induced primary astrocytes as well as in retinal ganglion cells following optic nerve crush, while treatment with 2Bact, a specific eIF2B activator, suppressed both the ISR and GDF15. In the VWMD model, CSF GDF15 levels corresponded with the magnitude of the ISR and were reduced by 2BAct. In VWM patients, mean CSF GDF15 was elevated >20‐fold as compared to healthy controls, whereas plasma GDF15 was undifferentiated.ConclusionsThese data suggest that CSF GDF15 is a dynamic marker of ISR activation in the CNS and may serve as a pharmacodynamic biomarker for ISR‐modulating therapies.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献